Clearmind Medicine Inc. · NASDAQ:CMND
Clearmind Medicine — Investor Presentation (July 2025)
24 slides from Clearmind Medicine's investor presentation, Jul 29, 2025
Slide 1: Novel Psychedelics for Treating Addictions, Obesity & Mental Health
www.ClearmindMedicine.com Novel Psychedelics for Treating Addictions, Obesity & Mental Health Corporate and Science Presentation | July 2025 NASDAQ: CMND FSE: CWY0 Clearmind Medicine Inc.
Slide 2: Forward-looking statements
Clearmind Medicine Inc. Page 2 All statements in this presentation, other than those relating to historical facts, are "forward-looking statements . ” Forward - looking statements contained in this presentation include, but are not limited to, statements regarding Clearmind Medicine Inc . (the “Comp
Slide 3: About Clearmind
About Clearmind Clearmind Medicine Inc. Corporate Presentation | July 2025 Why Psychedelics? Psychedelic compounds are increasingly being studied and many believe represent the future for treatment of a variety of mental health disorders. Clearmind’s solutions for addiction, especially alcoholism an
Slide 4: Pipeline
Pipeline Clearmind Medicine Inc. Page 4 Corporate Presentation | July 2025
Slide 5: Alcohol Use Disorder
Alcohol Use Disorder Only 4 FDA approved medicines for AUD Average $/Month Approved by FDA $42 1949 Antabuse Disulfiram $125 2004 Campral Acamprosate $205 1994 ReVia Naltrexone $1000 2006 Vivitrol Naltrexone Clearmind Medicine Inc. Page 5 Corporate Presentation | O c t o b e r 2024 Existing medicine
Slide 6: Alcohol Use Disorder among US Veterans: Treatment Gap
Alcohol Use Disorder (AUD) among US Veterans Treatment Gap Clearmind Medicine Inc. Page 6 Corporate Presentation | July 2025 Among those diagnosed with AUD annually (300,000+ cases), only about one - third receive any VA specialty addiction treatment. https:// www.hsrd.research.va.gov/publications/f
Slide 7: Clearmind's solution: flagship proprietary molecule MEAI
Clearmind’s solution is its flagship proprietary molecule: MEAI or 5 - Methoxy - 2 - aminoindane MEAI is a non - hallucinogenic psychoactive molecule of the 2 - aminoindane group. It is a synthetic small molecule with a streamlined and cost - effective synthesis Has been recreationally used by many
Slide 8: MEAI Mechanism of Action
MEAI Mechanism of Action The efficacy and mechanism of action of MEAI has been investigated in vitro as well as in vivo Clearmind Medicine Inc. Page 8 Corporate Presentation | July 2025 In vitro binding studies established interactions mainly with the serotonergic system. MEAI was found to interact
Slide 9: First In-Human Clinical Trials: CMND-100 for Alcohol Use Disorder
Clearmind’s First In - Human Clinical Trials: CMND - 100 for Alcohol Use Disorder Study design: Phase I/IIa The IIa will be a double - blind, placebo - controlled study Primary end point: to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single
Slide 10: Ongoing clinical programs: Clinical sites
Ongoing clinical programs: Clinical sites Clearmind Medicine Inc. Page 10 Corporate Presentation | July 2025 CMND - 100 for Alcohol Use Disorder Johns Hopkins School of Medicine Baltimore, MD, USA. Principal investigators: Jennifer Ellis, PhD and Professor Eric Strain, MD. Yale School of Medicine, D
Slide 11: Pre-clinical results in alcohol consumption
Pre - clinical results in alcohol consumption Pre - clinical in vivo trials demonstrated a significant and immediate reduction effect on alcohol consumption. The efficacy of MEAI in reducing alcohol consumption in mice was evaluated in an in vivo alcoholism model involving intermittent access to 20%
Slide 12: Pre-clinical results in treating Obesity
Pre - clinical results in treating Obesity • Led by Prof. Joseph Tam, DMD, PhD, head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, PhD. • 3 groups of animals • Evaluated multi - paramet
Slide 13: Pre-clinical results in treating Obesity
Pre - clinical results in treating Obesity Pre - clinical results in treating obesity Results for the 3 rd group - high - fat diet group treated with MEAI • Weight loss of 20% • Reduction in fat mass and preservation of lean body mass • Increased energy metabolism • No effect on motivation and well
Slide 14: Pre-clinical results for cocaine addiction
Pre - clinical results for cocaine addiction In vivo research studies suggested that MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process. MEAI’s effect on cocaine addiction was evaluated utilizing male Sprague Dawley rats (Bar - Ilan Universi
Slide 15: Pre-clinical results for cocaine addiction
Pre - clinical results for cocaine addiction The Effect of MEAI on the Substance - Use - Disorder (SUD) Rat Model using Cocaine as the Substance of Abuse The 5 mg/kg dose was also found to significantly reduce the preference for cocaine in the CPP paradigm and reduce cocaine craving and reinstatemen
Slide 16: MEAI Pre-clinical Safety
Corporate Presentation | October 2021 Medicine Inc. Page 16 MEAI Pre - clinical Safety Results demonstrated low toxicity and a strong safety profile Summary of the Toxicology program for MEAI
Slide 17: The Clearmind Advantage
The Clearmind Advantage Next - gen and non - hallucinogenic MEAI is a next generation psychedelic, that does not induce hallucinations and is not addictive. MEAI is potentially effective for alcoholism, cocaine addiction and obesity. Accessible treatment Historical human data In 2018, an MEAI - base
Slide 18: IP Portfolio
Consists of 19 utility patent families owned by the company* Claims include composition of matter and method of use MEAI : 2 mature families for binge behaviour regulators and alcoholic beverage substitute MEAI + PEA : 4 families for combination treatment for binge behaviour , cocaine addiction, obe
Slide 19: Strong and Experienced Management Team
Strong and Experienced Management Team Adi Zuloff - Shani, PhD Chief Executive Officer Dr. Adi Zuloff - Shani is a Biomedical Research and Development Executive with vast experience and over 20 years of strategic and operational leadership in the healthcare industry, as well as a deep understanding
Slide 20: Team of International Experts
Team of International Experts Amit Shwartz, MSc R&D Consultant Shannon Smadella Community Development Yael Stav, PhD Program Management Sara Horn, PhD Clinical and Regulatory Affairs Nick Kadysh Special Advisor Alcohol Substitute Program Gadi Levin, MBA VP Finance Clearmind Medicine Inc. Page 20 Cor
Slide 21: Award-Winning Advisory Board
Award - Winning Advisory Board Prof. Alon Friedman MD, PhD, Dalhousie University, Halifax, Canada Prof. Christian Schütz MD, PhD, University of British Columbia, Canada Prof. John Krystal MD , Yale University, CT, US Prof. Henry R. Kranzler MD, PhD, University of Pennsylvania, PA, US Prof. Fatima St
Slide 22: Award-Winning Advisory Board
Award - Winning Advisory Board Prof. Gabriele Fischer MD, PhD, Medical University Vienna, Austria Prof. Michael Davidson MD, Israeli Medical Centre for Alzheimer, Israel Prof. Gal Yadid PhD, Bar Ilan University, Israel Prof. Wim van den Brink MD, PhD, University of Amsterdam, The Netherlands Prof. J
Slide 23: Highly Accomplished Board of Directors
Highly Accomplished Board of Directors Asaf Itzhaik Director Amitay Weiss Chairman of the Board Oz Adler Director Yehonatan Shachar Director Mr . Asaf Itzhaik has served as our Director since November 2022 . Mr . Itzhaik is a seasoned international businessman in retail, BTC, BTB and real estate . H
Slide 24: Let's make history together
Let's make history t o g e t h e r . Clearmind Medicine Inc. Page 24 Corporate Presentation | July 2025 Join our journey Investor Relations US: CMND@crescendo - IR.com invest@clearmindmedicine.com clearmindmedicine.com
Clearmind Medicine — Investor Presentation (July 2025) on 6ix